Biocon Board Approves FY26 Results, 10% Dividend

• Approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, with FY26 consolidated net profit of ₹3,688 million.
• Recommended final dividend of 10% (₹0.50 per share) for FY26, with record date July 3, 2026 and payment by August 31, 2026.
• Approved acquisition of remaining ~2% stake in subsidiary Biocon Biologics Limited (BBL) via share swap issuing 8.79 million shares worth ₹330.73 crores.
• Appointed S.R. Batliboi as new statutory auditors and designated Dr. Anuj Goel and Mr. Susheel Umesh as Senior Management Personnel.